Amneal Pharmaceuticals (DB:2DT) - Hisse Senedi Fiyatı, Haberler ve Analizler

2DT Stoklara Genel Bakış

Amneal Pharmaceuticals, Inc. iştirakleri ile birlikte jenerik, enjektabl, biyobenzer ve özel markalı farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dünya çapında dağıtımını yapmaktadır. Daha fazla detay

2DT temel anali̇z
Kar Tanesi Skoru
Değerleme	6/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 81.8% daha düşük bir oranda işlem görüyor

Gelirin yılda 5.57% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Analistler hisse senedi fiyatının 24% oranında artacağı konusunda hemfikir

Risk Analizi

Negatif hissedar öz sermayesi

Son 3 ayda dalgalı hisse senedi fiyatı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Amneal Pharmaceuticals, Inc. Rakipler

Dermapharm Holding

XTRA:DMP

€1.9b

Bayer

XTRA:BAYN

€19.9b

PharmaSGP Holding

XTRA:PSG

€297.4m

Pierrel

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Amneal Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$8.05
52 Haftanın En Yüksek Seviyesi	US$8.55
52 Haftanın En Düşük Seviyesi	US$3.80
Beta	1.17
11 Aylık Değişim	5.23%
3 Aylık Değişim	17.52%
1 Yıllık Değişim	102.26%
33 Yıllık Değişim	101.25%
5 Yıllık Değişim	198.15%
Halka arzdan bu yana değişim	-56.27%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	2DT	DE Pharmaceuticals	DE Pazar
7D	5.9%	-7.5%	-0.2%
1Y	102.3%	-24.1%	8.3%

Getiri vs. Endüstri: 2DT geçen yıl % -24.1 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: 2DT geçen yıl % 8.3 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 2DT's price volatile compared to industry and market?
2DT volatility
2DT Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	8.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 2DT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 2DT 'nin haftalık oynaklığı ( 7% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2002	7,850	Chirag Patel	amneal.com

Amneal Pharmaceuticals, Inc. bağlı ortaklıkları ile birlikte jenerik, enjekte edilebilir, biyobenzer ve özel markalı farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dünya çapında dağıtımını yapmaktadır. Şirket üç segmentte faaliyet göstermektedir: Jenerik, Özel ve AvKARE. Jenerik segmenti, anında ve uzatılmış salımlı oral katı, toz, sıvı, steril enjekte edilebilir, burun spreyi, inhalasyon ve solunum, biyobenzer, oftalmik, film, transdermal yama ve topikal ürünler sunmaktadır.

Amneal Pharmaceuticals, Inc. Temel Bilgiler Özeti

Amneal Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
2DT temel i̇stati̇sti̇kler
Piyasa değeri	€2.65b
Kazançlar(TTM)	-€175.21m
Gelir(TTM)	€2.55b

1.0x

P/S Oranı

-14.2x

F/K Oranı

2DT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
2DT gelir tablosu (TTM)
Gelir	US$2.68b
Gelir Maliyeti	US$1.70b
Brüt Kâr	US$979.05m
Diğer Giderler	US$1.16b
Kazançlar	-US$184.45m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.60
Brüt Marj	36.53%
Net Kâr Marjı	-6.88%
Borç/Özkaynak Oranı	-7,524.6%

2DT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

2DT Stoklara Genel Bakış

Ödüller

Risk Analizi

Amneal Pharmaceuticals, Inc. Rakipler

XTRA:DMP

€1.9b

XTRA:BAYN

€19.9b

XTRA:PSG

€297.4m

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold €236k worth of stock

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors